ERBB2 and lymphangioma: Even if increasing attention is given to the specificities of patients with CNS involvement and several anti‐HER2 targeted agents have demonstrated antitumor activity in the brain,20, 21, 22, 23, 24, 25 still little is known regarding the characteristics and clinical outcomes of patients with HER2‐positive breast cancer and LM.